Kathryn Parsons-Reponte is a corporate associate in the San Diego office of Latham & Watkins and is a member of the firm’s Healthcare & Life Sciences and Privacy & Cyber Practices.
Kathryn counsels international and domestic clients on legal and business issues relating to privacy and security, technology, intellectual property, and commercial deals across a wide range of industries, including healthcare and digital health, pharmaceutical, biotechnology, diagnostic, medical device, and other life sciences industries.
Prior to her law career, Kathryn worked in research and development at Genentech on a team that brought a novel antibody drug conjugate for the treatment of breast cancer to market. Kathryn uses her pragmatic understanding of the legal and business challenges of established and emerging companies to drive engagements that bring innovations to market, including advising on:
- Strategic licensing and collaborations
- Technology transfers
- Joint venture agreements
- Venture financing, public offering, M&A, and other strategic transactions
- Manufacturing, supply, distribution, and other commercial agreements
- Clinical trial agreements
Kathryn holds the Certified Information Privacy Professional/United States (CIPP/US) credential, a global gold standard and key industry benchmark accredited by the International Association of Privacy Professionals (IAPP) that demonstrates a strong understanding of US privacy laws and regulations.
- Co-Author, “How Industry Can Tackle Data Privacy,” Automotive News, May, 2021
- Co-Author, “Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate,” Cancer Res 2008; 68: 9280-9290
- Co-Author, “Ligand-Independent HER2/HER3/PI3K Complex is Disrupted by Trastuzumab and is Effectively Inhibited by the PI3K Inhibitor GDC-0941,” Cancer Cell 2009; 15(5) :429-440
- Co-Author, “Superior In Vivo Efficacy Of Afucosylated Trastuzumab In The Treatment of HER2 Amplified Breast Cancer,” Cancer Res 2010; 70(11): 4481-4489
- Co-Author, “Trastuzumab-DM1 (T-DM1) Retains All The Mechanism Of Action Of Trastuzumab and Efficiently Inhibits Growth Of Lapatinib Insensitive Breast Cancer,” Breast Cancer Res Treat 2011; 128(2): 347-56
- Co-Author, “Engineered thio-trastuzumab-DM1 Conjugate With An Improved Therapeutic Index To Target HER2-positive Breast Cancer,” Clin Cancer Res 2010; 16(19): 4769-78
- Co-Author, “Conjugation Site Modulates the in vivo Stability and Therapeutic Activity of Antibody-Drug Conjugates,” Nature Biotech 2012; 30(2): 184-9
- Co-Author, “Effects of anti-VEGF on Pharmacokinetics, Biodistribution, and Tumor Penetration of Trastuzumab in a Preclinical Breast Cancer Model,” Mol Cancer Therapeutics 2012; 11(3): 752-62
- Co-Author, “Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering, “ J Med Chem 2014; 57(19): 7890-9
- Co-Author, “Trastuzumab directed cytotoxic therapy: Efficacy against HER2-positive trastuzumab-insensitive breast cancer models and enhanced response in trastuzumab-sensitive models.” 2007 AACR Conference, (#649)
- Co-Author, “Potent Anti-tumor Activity Of T-DM1 Antibody-Drug Conjugate In Combination With Chemotherapeutic Agents In Breast Tumor Cells,” 2010 EORTC-NCI-AACR (#86)